The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: Early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis

APMIS

Volumn 119, Issue 8, 2011, Pages 498-504

  Risum, Malene ^a   Madelung, Ann ^b   Bondo, Henrik ^b   Bzorek, Michael ^b   Kristensen, Michael Holmsgaard ^b   Stamp, Inger Merete ^b   Hasselbalch, Hans Carl ^a  

^a ROSKILDE HOSPITAL   (Denmark)

^b NAESTVED HOSPITAL   (Denmark)

Author keywords

Allele burden; Early myelofibrosis; Essential thrombocythemia; JAK2V617F; Polycythemia vera

Indexed keywords

GUANINE; JANUS KINASE; RETICULIN; STAT3 PROTEIN; STAT5 PROTEIN; THYMINE;

ALLELE; ARTICLE; BONE MARROW BIOPSY; CELL PROLIFERATION; CHRONIC DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; ERYTHROPOIESIS; EXON; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GRANULOPOIESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MYELOFIBROSIS; NEUTROPHIL; PHOSPHORYLATION; POLYCYTHEMIA VERA; PREFIBROTIC MYELOFIBROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTHEMIA;

ALLELES; BIOPSY; BONE MARROW NEOPLASMS; CROSS-SECTIONAL STUDIES; DNA; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; PHOSPHORYLATION; POLYCYTHEMIA VERA; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY MYELOFIBROSIS; RETROSPECTIVE STUDIES; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; STATISTICS, NONPARAMETRIC; THROMBOCYTHEMIA, ESSENTIAL;

EID: 79960239128     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02754.x     Document Type: Article

References (22)

1. Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlué J, et al. JAK2V617F allele burden discriminates in essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009;37:1186-93.
2. Hasselbalch HC. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated haematological cancer Time to change our therapeutic attitude with early upfront treatment?. Leuk Res 2009;33:11-8.
3. Naresh KN. Classification of Philadelphia translocation-negative myeloproliferative neoplasms: its impact on data from clinical trials. J Clin Oncol 2009;27:e175-6.
4. Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 2010;56:758-67.
5. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.
6. Larsen TS, Hasselbalch HC, Pallisgaard N, Møller MB. Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia. APMIS 2007;115:1267-73.
7. Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol 2009;27:2991-9.
8. Swerdlow SH, editor. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Geneva, Switzerland: WHO Press, 2008.
9. Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis-impact on disease phenotype. Eur J Haematol 2007;79:508-15.
10. Hussein K, Bock O, Kreipe H. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers. Pathology 2007;74:72-80.
11. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83.
12. Tefferi A, Lasho TL, Huang J, Finke C, Mesa RA, Li CY, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukaemia-free survival. Leukemia 2008;22:756-61.
13. Thiele J. Philadelphia chromosome-negative chronic myeloproliferative disease. Am J Clin Pathol 2009;132:261-80.
14. Tefferi A, Thiele J, Vardiman JW. The 2008 World health organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009;115:3842-7.
15. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 2010;91:174-9.
16. Cankovic M, Whiteley L, Hawley RC, Zarbo RJ, Chitale D. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory. Am J Clin Pathol 2009;132:713-21.
17. Teofili L, Martini M, Cenci T, Petrucci G, Torti L, Storti S, et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617 JAK-2 mutation. Blood 2007;110:354-9.
18. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntley BJP, et al. Mutation of the JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations and role in leukemic transformation. Blood 2006;108:3548-55.
19. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008;112:2190-6.
20. Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, et al. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlated with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol 2007;31:233-9.
21. Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, et al. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signalling. Exp Hematol 2007;35:1695-703.
22. Campbell PJ, Green AR. Management of polycythemia vera and essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2005:201-8.